文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

预防性扩大野照射与盆腔照射在2018 FIGO IIIC1期宫颈癌患者中的比较

Prophylactic Extended-Field Irradiation Versus Pelvic Irradiation in Patients With Cervical Cancer With 2018 FIGO Stage IIIC1 Disease.
PubMed 文献 · Pract Radiat Oncol · 2023-04-17

该回顾性研究纳入2011至2015年在本院接受根治性同步放化疗的2018 FIGO IIIC1期宫颈癌患者280例,比较预防性扩大野放疗(EFRT)与盆腔放疗(PRT)的生存率和毒性。倾向评分匹配后,EFRT组5年总生存率和无病生存率均优于PRT组,但≥3级慢性毒性发生率在EFRT组数值更高、差异未达统计学显著。

要点

  • 匹配后EFRT组5年总生存率85.0% vs PRT组61.9%(P = .025),无病生存率77.9% vs 53.0%(P = .004)。
  • 高危组和低危组中EFRT均较PRT显著改善无病生存率。
  • ≥3级慢性毒性PRT组1.2% vs EFRT组5.9%(P = .067),差异未达统计学显著。

核心结论

  • 与PRT相比,预防性EFRT与2018 FIGO IIIC1期宫颈癌患者总生存率、无病生存率和腹主动脉旁淋巴结控制改善相关。
  • EFRT组≥3级毒性发生率高于PRT组,但差异未达统计学显著。

研究设计与样本

  • 回顾性分析2011至2015年在本院接受根治性同步放化疗的2018 FIGO IIIC1期宫颈癌患者。
  • 共纳入280例,PRT组161例、EFRT组119例;倾向评分匹配(1:1)后选出71对患者。
  • 盆腔区域(PRT)或盆腔加腹主动脉旁淋巴结区域(EFRT)接受50.4 Gy/28次调强放疗,同步化疗一线方案为每周顺铂。

主要发现

  • 匹配后PRT组与EFRT组5年总生存率分别为61.9%和85.0%(P = .025)。
  • 匹配后PRT组与EFRT组5年无病生存率分别为53.0%和77.9%(P = .004)。
  • 按阳性髂总淋巴结、≥3枚盆腔淋巴结、2014 FIGO IIIB期3个因素分为高危组(122例)和低危组(158例),两组中EFRT均较PRT显著改善无病生存率。
  • ≥3级慢性毒性发生率PRT组1.2% vs EFRT组5.9%(P = .067),差异未达统计学显著。

关键数值与推荐

  • 盆腔或盆腔加腹主动脉旁淋巴结区域放疗剂量为50.4 Gy/28次,采用调强放疗。
  • 同步化疗一线方案为每周顺铂。
  • 高危组定义为具有阳性髂总淋巴结、≥3枚盆腔淋巴结、2014 FIGO IIIB期中的3个因素;低危组为其余患者。

临床怎么用

  • 原文未据此给出推荐。
  • 作者结论指出,与PRT相比,预防性EFRT与2018 FIGO IIIC1期宫颈癌患者总生存率、无病生存率和腹主动脉旁淋巴结控制改善相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to compare the survival rates and toxicities of prophylactic extended-field radiation therapy (EFRT) and pelvic radiation therapy (PRT) among patients with cervical cancer with 2018 International Federation of Gynecology and Obstetrics (FIGO) stage IIIC1 disease. METHODS AND MATERIALS: We retrospectively analyzed patients with 2018 FIGO stage IIIC1 disease who were treated with definitive concurrent chemoradiotherapy at our institute between 2011 and 2015. A dose of 50.4 Gy in 28 fractions was delivered to the pelvic region (by PRT) or the pelvic plus para-aortic lymph node region (by EFRT) with intensity modulated radiation therapy. The first-line regimen of concurrent chemotherapy was weekly cisplatin. RESULTS: A total of 280 patients were included, with 161 patients treated with PRT and 119 patients treated with EFRT. After propensity score matching (1:1), 71 pairs of patients were selected. The respective 5-year rates of the patients treated with PRT and EFRT were 61.9% and 85.0% for overall survival (P = .025) and 53.0% and 77.9% for disease-free survival (DFS) (P = .004), respectively, after matching. In the subgroup analysis, patients were grouped into a high-risk group (122 patients) and a low-risk group (158 patients) based on 3 factors: positive common iliac lymph nodes, ≥3 pelvic lymph nodes, and 2014 FIGO stage IIIB disease. In both the high-risk and low-risk groups, EFRT significantly improved DFS compared with PRT. The rates of grade ≥3 chronic toxicities were 1.2% and 5.9% in the PRT and EFRT groups, respectively (P = .067). CONCLUSIONS: In comparison to PRT, prophylactic EFRT was associated with improved overall survival, DFS, and para-aortic lymph node control in patients with cervical cancer with FIGO stage IIIC1 disease. The incidence of grade ≥3 toxicities was higher in the EFRT group than in the PRT group, although the difference was not significant.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Wang W, Meng Q, Zhou Y, et al. Prophylactic Extended-Field Irradiation Versus Pelvic Irradiation in Patients With Cervical Cancer With 2018 FIGO Stage IIIC1 Disease. Pract Radiat Oncol. 2023. PMID: 37075837. doi:10.1016/j.prro.2023.03.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。